Document is current
Any future updates will be listed below
-
Authors
Tanevski, Jovan https://orcid.org/0000-0001-7177-1003
Vulliard, Loan https://orcid.org/0000-0002-2260-4935
Ibarra-Arellano, Miguel A.
Schapiro, Denis https://orcid.org/0000-0002-9391-5722
Hartmann, Felix J. https://orcid.org/0000-0002-4174-2276
Saez-Rodriguez, Julio https://orcid.org/0000-0002-8552-8976
-
Funding
Funding for this research was provided by:
Bruno und Helene Jöster Stiftung
State Parliament of Baden-Württemberg for the Innovation Campus Health + Life Science Alliance Heidelberg Mannheim
- License Information
-
More Information
Article History
Received: 26 March 2024
Accepted: 23 April 2025
First Online: 30 April 2025
Competing interests
: J.S.R. reports in the last 3 years funding from GSK and Pfizer, and fees/honoraria from Travere Therapeutics, Stadapharm, Astex, Pfizer, Owkin, Moderna and Grunenthal. D.S. reports funding from Cellzome, a GSK company and received fees and honorariums from Immunai, Noetik, Alpenglow and Lunaphore. The remaining authors declare no competing interests.
